Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Déjà vu all over again.

Saag MS, Dumond JB.

AIDS. 2019 Nov 1;33(13):2097-2098. doi: 10.1097/QAD.0000000000002314. No abstract available.

PMID:
31577573
2.

Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.

Greene SA, Chen J, Prince HMA, Sykes C, Schauer AP, Blake K, Nelson JAE, Gay CL, Cohen MS, Dumond JB.

Clin Pharmacol Ther. 2019 Oct;106(4):821-830. doi: 10.1002/cpt.1464. Epub 2019 May 31.

PMID:
31002391
3.

The potential pitfalls of PrEP.

Cottrell ML, Dumond JB.

Lancet HIV. 2018 Nov 29. pii: S2352-3018(18)30318-7. doi: 10.1016/S2352-3018(18)30318-7. [Epub ahead of print] No abstract available.

PMID:
30503323
4.

Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.

Dumond JB, Greene SA, Prince HMA, Chen J, Maas BM, Sykes C, Schauer AP, Blake KH, Nelson JAE, Gay CL, Kashuba ADM, Cohen MS.

Antivir Ther. 2019;24(1):45-50. doi: 10.3851/IMP3277.

PMID:
30375984
5.

A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.

Garrett KL, Chen J, Maas BM, Cottrell ML, Prince HA, Sykes C, Schauer AP, White N, Dumond JB.

J Pharmacol Exp Ther. 2018 Nov;367(2):245-251. doi: 10.1124/jpet.118.251009. Epub 2018 Aug 27.

6.

Pharmacogenetic Analysis of the Model-Based Pharmacokinetics of Five Anti-HIV Drugs: How Does This Influence the Effect of Aging?

Chen J, Akhtari FS, Wagner MJ, Suzuki O, Wiltshire T, Motsinger-Reif AA, Dumond JB.

Clin Transl Sci. 2018 Mar;11(2):226-236. doi: 10.1111/cts.12525. Epub 2017 Dec 3.

7.

Comparison of tenofovir plasma and tissue exposure using a population pharmacokinetic model and bootstrap: a simulation study from observed data.

Collins JW, Heyward Hull J, Dumond JB.

J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):631-640. doi: 10.1007/s10928-017-9554-9. Epub 2017 Nov 8.

8.

Effect of Trospium Chloride on Cognitive Function in Women Aged 50 and Older: A Randomized Trial.

Geller EJ, Dumond JB, Bowling JM, Khandelwal CM, Wu JM, Busby-Whitehead J, Kaufer DI.

Female Pelvic Med Reconstr Surg. 2017 Mar/Apr;23(2):118-123. doi: 10.1097/SPV.0000000000000374.

PMID:
28067745
9.

Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection.

Maas BM, Francis O, Mollan KR, Lee C, Cottrell ML, Prince HM, Sykes C, Trezza C, Torrice C, White N, Malone S, Hudgens MG, Sharpless NE, Dumond JB.

PLoS One. 2016 Dec 30;11(12):e0168709. doi: 10.1371/journal.pone.0168709. eCollection 2016.

10.

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.

Dumond JB, Chen J, Cottrell M, Trezza CR, Prince H, Sykes C, Torrice C, White N, Malone S, Wang R, Patterson KB, Sharpless NE, Forrest A.

CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):128-135. doi: 10.1002/psp4.12151. Epub 2016 Dec 29.

11.

p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.

Dumond JB, Collins JW, Cottrell ML, Trezza CR, Prince H, Sykes C, Torrice C, White N, Malone S, Wang R, Patterson KB, Sharpless NE, Forrest A.

CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):120-127. doi: 10.1002/psp4.12150. Epub 2016 Dec 26.

12.

Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.

Chen J, Malone S, Prince HM, Patterson KB, Dumond JB.

CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):147-57. doi: 10.1002/psp4.12065. Epub 2016 Mar 22.

13.

Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.

Dumond JB, Francis O, Cottrell M, Trezza C, Prince HM, Mollan K, Sykes C, Torrice C, White N, Malone S, Wang R, Van Dam C, Patterson KB, Hudgens MG, Sharpless NE, Forrest A.

Antivir Ther. 2016;21(5):441-5. doi: 10.3851/IMP3017. Epub 2016 Jan 5.

14.

Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells.

Dumond JB, Yang KH, Kendrick R, Reddy YS, Kashuba AD, Troiani L, Bridges AS, Fiscus SA, Forrest A, Cohen MS.

Antimicrob Agents Chemother. 2015 Oct;59(10):6395-401. doi: 10.1128/AAC.01148-15. Epub 2015 Aug 3.

15.

Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.

Dumond JB, Rigdon J, Mollan K, Tierney C, Kashuba AD, Aweeka F, Collier AC.

J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):510-4. doi: 10.1097/QAI.0000000000000777.

16.

Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.

Greener BN, Patterson KB, Prince HM, Sykes CS, Adams JL, Dumond JB, Shaheen NJ, Madanick RD, Dellon ES, Cohen MS, Kashuba AD.

J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):39-44. doi: 10.1097/QAI.0b013e31829ed7a4.

17.

Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.

Adams JL, Patterson KB, Prince HM, Sykes C, Greener BN, Dumond JB, Kashuba AD.

Antivir Ther. 2013;18(8):1005-13. doi: 10.3851/IMP2665. Epub 2013 Jul 31.

18.

Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.

Dumond JB, Adams JL, Prince HM, Kendrick RL, Wang R, Jennings SH, Malone S, White N, Sykes C, Corbett AH, Patterson KB, Forrest A, Kashuba AD.

HIV Med. 2013 Aug;14(7):401-9. doi: 10.1111/hiv.12017. Epub 2013 Feb 24.

19.

Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.

Patterson KB, Dumond JB, Prince HA, Jenkins AJ, Scarsi KK, Wang R, Malone S, Hudgens MG, Kashuba AD.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):51-8. doi: 10.1097/QAI.0b013e31827fd47e.

20.

Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.

Wohl DA, Dumond JB, Blevins S, Pittard D, Ragan D, Wang R, Massengale K, Walsh K, Floris-Moore M, Eron JJ Jr, Richardson A, Hudgens MG, Kashuba AD.

Antimicrob Agents Chemother. 2013 Feb;57(2):784-8. doi: 10.1128/AAC.01826-12. Epub 2012 Nov 26.

21.

Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.

Dumond JB, Nicol MR, Kendrick RN, Garonzik SM, Patterson KB, Cohen MS, Forrest A, Kashuba AD.

Clin Pharmacokinet. 2012 Dec;51(12):809-22. doi: 10.1007/s40262-012-0012-y.

22.

Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women.

Geller EJ, Crane AK, Wells EC, Robinson BL, Jannelli ML, Khandelwal CM, Connolly A, Parnell BA, Matthews CA, Dumond JB, Busby-Whitehead J.

Clin Drug Investig. 2012 Oct 1;32(10):697-705. doi: 10.2165/11635010-000000000-00000.

23.

Pre-exposure prophylaxis for HIV prevention: how to predict success.

Kashuba AD, Patterson KB, Dumond JB, Cohen MS.

Lancet. 2012 Jun 30;379(9835):2409-2411. doi: 10.1016/S0140-6736(11)61852-7. Epub 2011 Dec 6. No abstract available.

24.

Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers.

Kwara A, Tashima KT, Dumond JB, Poethke P, Kurpewski J, Kashuba AD, Court MH, Greenblatt DJ.

Antimicrob Agents Chemother. 2011 Jul;55(7):3527-33. doi: 10.1128/AAC.00980-10. Epub 2011 Apr 25.

25.

Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.

Brown KC, Patterson KB, Malone SA, Shaheen NJ, Prince HM, Dumond JB, Spacek MB, Heidt PE, Cohen MS, Kashuba AD.

J Infect Dis. 2011 May 15;203(10):1484-90. doi: 10.1093/infdis/jir059.

26.

A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.

Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD.

Clin Pharmacol Ther. 2010 Jun;87(6):735-42. doi: 10.1038/clpt.2009.253. Epub 2010 Feb 10.

27.

Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.

Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, Tressler R, Worsley J, Kashuba AD.

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):546-53. doi: 10.1097/QAI.0b013e3181ae69c5.

28.

Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.

Yeh RF, Rezk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, Chen YC, Vourvahis M, Horton AL, Fiscus SA, Patterson KB.

Antimicrob Agents Chemother. 2009 Jun;53(6):2367-74. doi: 10.1128/AAC.01523-08. Epub 2009 Mar 23.

29.

Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.

Dumond JB, Reddy YS, Troiani L, Rodriguez JF, Bridges AS, Fiscus SA, Yuen GJ, Cohen MS, Kashuba AD.

J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):156-62. doi: 10.1097/QAI.0b013e31816de21e.

30.

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, Bridges AS, Stewart PW, Cohen MS, Kashuba AD.

AIDS. 2007 Sep 12;21(14):1899-907.

Supplemental Content

Loading ...
Support Center